CRISPR Therapeutics AG (NASDAQ: CRSP) stock is set to open sharply lower, plummeting 8.86% in pre-market trading on Tuesday, following the release of disappointing second-quarter financial results. The gene-editing focused biopharmaceutical company reported figures that fell significantly short of analyst expectations, raising concerns among investors about its near-term financial performance.

For the quarter ended June 30, 2025, CRISPR Therapeutics reported revenue of $892,000, missing the analyst consensus estimate of $6.255 million by a wide margin. This represents a 72.53% increase from the same period last year but failed to meet market expectations. The company's net loss expanded to $208.5 million, or $2.40 per share, compared to a loss of $126.4 million, or $1.49 per share, in the second quarter of 2024. The increased loss was partly attributed to a $96.3 million expense for acquired in-process research and development.

Despite the financial setback, CRISPR Therapeutics highlighted some positive developments, including the activation of 75 authorized treatment centers for its CASGEVY therapy and advancements in various clinical trials. The company maintains a strong balance sheet with approximately $1.7 billion in cash and marketable securities. However, investors seem to be focusing on the near-term financial performance, leading to the significant pre-market stock decline. As the market opens, all eyes will be on how CRISPR Therapeutics addresses these concerns and outlines its strategy to improve financial results in the coming quarters.